China, India Focus Of Lilly Plans To Market Off-patent Drugs
This article was originally published in PharmAsia News
Executive Summary
China, as well as India, are seen by U.S.-based Eli Lilly as major testing grounds for a strategy of marketing off-patent drugs in competition with generic versions